| Number of patients | 31 |
| Median age, y (range) | 46 (18-64) |
| Female/male, n | 12/19 |
| Diagnosis | |
| AML/MDS | 13 |
| ALL | 5 |
| NHL | 5 |
| HL | 5 |
| Other | 3 |
| CMV serostatus | |
| D+/R+ | 16 |
| D+/R- | 4 |
| D-/R+ | 6 |
| D-/R- | 5 |
| Conditioning, MA/RIC | 13/18 |
| Median CD34+ cells/kg infused | 5.46x10e6 (2.24-11.4) |
| CMV reactivation | |
| 1 episode | 24 |
| 2 or more episodes | 15 |
| Treatment | |
| G-CSF | 26 |
| Only platelet transfusion | 5 |
| Boost CD34+ | 4 |
| TPO receptor agonist | 2 |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.